We are live on ! Find out more
ZSAN

Zosano Pharma Corporation

Delisted

ZSAN was delisted on the 10th of June, 2022.

30 hedge funds and large institutions have $2.97M invested in Zosano Pharma Corporation in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

6% less funds holding

Funds holding: 3230 (-2)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

47% less capital invested

Capital invested by funds: $5.61M → $2.97M (-$2.64M)

Holders
30
Holders Change
-2
Holders Change %
-6.25%
% of All Funds
0.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
9
Reduced
2
Closed
8
Calls
Puts
Net Calls
Net Calls Change

ZSAN Hedge Fund Activity: Q1 2022 in Review

30 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Zosano Pharma Corporation (ZSAN) for Q1 2022, worth a combined $2.97M — down 47% from $5.61M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ZSAN and 6 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 9 added.

The largest buyer was Vanguard Group, adding an estimated $257K. The largest seller was Barclays, cutting an estimated $47.2K.

  • 30 institutional investors held Zosano Pharma Corporation (ZSAN) as of Q1 2022, down from 32 in Q4 2021.
  • Funds reported $2.97M of Zosano Pharma Corporation stock for Q1 2022, down 47% quarter-over-quarter.
  • 6 funds opened new Zosano Pharma Corporation positions in Q1 2022 and 8 closed out, a net change of -2 holders.
  • The largest Zosano Pharma Corporation buyer in Q1 2022 was Vanguard Group, an estimated $257K added.
  • The largest Zosano Pharma Corporation seller in Q1 2022 was Barclays, an estimated $47.2K sold.

Based on aggregated 13F filings for Q1 2022.